AIM ImmunoTech has announced key milestones in its ongoing Phase 2 study testing its drug Ampligen (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for patients with metastatic pancreatic cancer who have stable disease following FOLFIRINOX therapy.

 

The DURIPANC trial, an investigator-initiated, exploratory, open-label study at a single center, has enrolled 18 patients to date. The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands.

 

Lead investigator Marjolein YV Homs of Erasmus MC Cancer Institute, highlighted the encouraging results: “The promising Progression-Free Survival and Overall Survival seen in Phase 1 of the study – which supported advancement to the ongoing Phase 2 portion of the study – continue to be seen and enrollment is ongoing.” Detailed data are expected to be published later this year.

 

Erasmus MC also reported a favorable safety profile: “There has been no significant toxicity – an encouraging safety profile for a post-chemo setting – and Ampligen subjects are consistently reporting ‘high quality of life’ during treatment.”